Ovid Therapeutics Inc —— 财务报表 (NASDAQ:OVID) | MetaTrader

展开完整图表

新闻

Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript

3 Best Stocks to Buy Today, 4/7/2026, According to Top Analysts - TipRanks.com

Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding

Ovid Therapeutics Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:OVID) 2026-03-19

Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates

Niagen Bioscience (NAGE) Tops Q4 Earnings and Revenue Estimates

PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates

Ovid Therapeutics: Bullish Post-PIPE With Two Differentiated CNS Moonshots

Ovid’s KCC2 activator shows promising safety in early trial

Ovid Therapeutics股东批准增加授权股份及相关提案

Ovid Therapeutics shareholders approve increase in authorized shares and related proposals

Roth/MKM 给予 Ovid Therapeutics 股票"买入"评级，看好其癫痫药物